Cheng Zhong

Dr. Cheng Zhong


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Disease Markers
Verified
Journal Article
Open access
CZCheng Zhong
Cheng Zhong
LJLiang Jiahua
Liang Jiahua
ZCZhen Chen
Zhen Chen
LZLi-Ping Zhong
Li-Ping Zhong
GSGuodong Sun
Guodong Sun
YLYu-Ming Li
Yu-Ming Li
The most frequent internal modification in eukaryotic mRNA is N6-methyladenosine (m6A). However, what we know about the m6A regulators in Ankylosing spondylitis (AS) is still limited. In our study, eight distinct m6A regulators were selected utilizing Differentially Expressed Gene (DEG) analysis of the Gene Expression Omnibus GSE73754 dataset for making comparisons between AS (Ankylosing spondylitis) and non-AS patients. The random forest model and the nomogram model were used to screen the eight candidate m6A regulators and evaluate their prediction accuracy for the occurrence of AS. Furthermore, based on the selected m6A regulators, the AS patients were divided into two subgroups, and we applied principal component analysis algorithms to calculate their m6A score and evaluate the m6A patterns. Our findings revealed that patients in cluster A were linked to activated CD4 T cell immunity and activated CD8 T cell immunity. With its major contributions in the area of immunology, our research in m6A patterns may benefit the future diagnosis and treatment strategies of AS.

1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
YZYongping Zhang
Yongping Zhang
PSPing Sui
Ping Sui
CZCheng Zhong
Cheng Zhong
JLJiansheng Liu
Jiansheng Liu
Background: Hepatocellular carcinoma often results in late-stage diagnosis, leading to decreased treatment success. To improve prognosis, this study integrates cuproptosis with immune risk scoring models for HCC patients.

1 August 2025 in Oncologie
Verified
Journal Article
Open access
PDF file
ZDZhijun Ding
Zhijun Ding
YLYi Li
Yi Li
CZCheng Zhong
Cheng Zhong
Objectives: Osteosarcoma, a prevalent malignant bone tumor in pediatric and adolescent populations, is characterized by a markedly diverse tumor microenvironment (TME) that complicates therapeutic intervention. Among the key components of the TME, M2 macrophages contribute to immune suppression, tumor progression, and resistance to therapy. This study aims to explore the immune microenvironment of osteosarcoma and identify key immunosuppressive components using integrated transcriptomic analysis. Methods: We integrated scRNA-seq (GSE152048) and bulk RNA-seq (TARGET) data to characterize the osteosarcoma tumor microenvironment. Key analyses included cell clustering and annotation (Seurat), pseudotime trajectory (Monocle 2), cell-cell communication (CellChat), and M2 macrophage deconvolution (CIBERSORT, BayesPrism). Gene modules were identified via WGCNA, and drug sensitivity was predicted using oncoPredict. Key genes were validated by qRT-PCR and Western blot. Results: Our integrated analysis revealed that M2 macrophage infiltration was significantly associated with an immunosuppressive tumor microenvironment in osteosarcoma. Weighted gene co-expression network analysis (WGCNA) identified gene modules highly correlated with M2 macrophage abundance and immune evasion signatures. Reduced M2 infiltration was linked to altered transcriptional patterns and increased predicted sensitivity to Etoposide and Doxorubicin. Two immune-related genes, PTK2B and PTPRC, were significantly upregulated in osteosarcoma samples and validated by RT-qPCR and Western blotting in U2OS cells. Conclusions: This study demonstrates that M2 macrophage infiltration is a defining feature of the osteosarcoma immune microenvironment and is associated with immune suppression. Through integrative transcriptomic analysis, PTK2B and PTPRC were identified as key immune-related genes linked to M2 macrophage abundance and patient prognosis. These results establish a transcriptional basis for the immunosuppressive phenotype in osteosarcoma.